ExchangeDEX+

Buy Crypto Markets Spot FuturesXAUT Earn Event Center

Biotech and BNB treasury firm Windtree Therapeutics fell 77% on Wednesday after informing the SEC that it would be delisted from the Nasdaq stock exchange. Windtree Therapeutics, a biotech company that established a BNB treasury strategy last month, fell 77% on Wednesday after the Nasdaq informed the firm it would be delisted from the stock exchange for failing to meet compliance requirements.The noncompliance concerned Nasdaq Listing Rule 5550(a)(2) that requires a company’s stock to maintain a minimum bid price of $1.00 per share, Windtree stated in a filing to the US securities regulator on Tuesday. Nasdaq will suspend WINT trading on Thursday. Windtree (WINT) shares dropped a staggering 77.2% to $0.11 on the news, and are down another 4.7% in after-hours, Google Finance data shows. WINT shares saw a minor rise on July 16, when it announced its BNB treasury strategy, but have fallen over 90% since its July 18 peak.Read more Biotech and BNB treasury firm Windtree Therapeutics fell 77% on Wednesday after informing the SEC that it would be delisted from the Nasdaq stock exchange. Windtree Therapeutics, a biotech company that established a BNB treasury strategy last month, fell 77% on Wednesday after the Nasdaq informed the firm it would be delisted from the stock exchange for failing to meet compliance requirements.The noncompliance concerned Nasdaq Listing Rule 5550(a)(2) that requires a company’s stock to maintain a minimum bid price of $1.00 per share, Windtree stated in a filing to the US securities regulator on Tuesday. Nasdaq will suspend WINT trading on Thursday. Windtree (WINT) shares dropped a staggering 77.2% to $0.11 on the news, and are down another 4.7% in after-hours, Google Finance data shows. WINT shares saw a minor rise on July 16, when it announced its BNB treasury strategy, but have fallen over 90% since its July 18 peak.Read more

BNB treasury firm plunges 77% after Nasdaq delisting notice

2025/08/21 12:22

Biotech and BNB treasury firm Windtree Therapeutics fell 77% on Wednesday after informing the SEC that it would be delisted from the Nasdaq stock exchange.

Windtree Therapeutics, a biotech company that established a BNB treasury strategy last month, fell 77% on Wednesday after the Nasdaq informed the firm it would be delisted from the stock exchange for failing to meet compliance requirements.

The noncompliance concerned Nasdaq Listing Rule 5550(a)(2) that requires a company’s stock to maintain a minimum bid price of $1.00 per share, Windtree stated in a filing to the US securities regulator on Tuesday. Nasdaq will suspend WINT trading on Thursday.

Windtree (WINT) shares dropped a staggering 77.2% to $0.11 on the news, and are down another 4.7% in after-hours, Google Finance data shows. WINT shares saw a minor rise on July 16, when it announced its BNB treasury strategy, but have fallen over 90% since its July 18 peak.

Market Opportunity

CreatorBid Price(BID)

$0.0288

$0.0288$0.0288

-0.89%

USD

CreatorBid (BID) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.